FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Lansbury

Research Profile

Chemicals & Drugs

Disorders

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Procedures

Microscopy, Atomic Force

Phenomena

Circular Dichroism

Physiology

Co-author Network

Publications

TOP 3
Katherina Vamvaca; Peter T Lansbury; Leonidas Stefanis
N-terminal deletion does not affect α-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast.
Richard J Nowak; Gregory D Cuny; Sungwoon Choi; Peter T Lansbury; Soumya S Ray
Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods.
Katherina Vamvaca; Michael J Volles; Peter T Lansbury
The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Lansbury (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Katherina Vamvaca; Peter T Lansbury; Leonidas Stefanis
N-terminal deletion does not affect α-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast.
Journal of neurochemistry 2011;119(2):389-97.
2010: Richard J Nowak; Gregory D Cuny; Sungwoon Choi; Peter T Lansbury; Soumya S Ray
Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods.
Journal of medicinal chemistry 2010;53(7):2709-18.
2009: Katherina Vamvaca; Michael J Volles; Peter T Lansbury
The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast.
Journal of molecular biology 2009;389(2):413-24.
2009: Zhihua Liu; Robin K Meray; Tom N Grammatopoulos; Ross A Fredenburg; Mark Cookson; Yichin Liu; Todd Logan; Peter T Lansbury
Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(12):4635-40.
2008: Katerina E Paleologou; Adrien Schmid; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Ross A Fredenburg; Peter T Lansbury; Claudio O Fernandez; David Eliezer; Markus Zweckstetter; Hilal A Lashuel
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.
The Journal of biological chemistry 2008;283(24):16895-905.
2008: Marta Martinez-Vicente; Zsolt Talloczy; Susmita Kaushik; Ashish C Massey; Joseph Mazzulli; Eugene V Mosharov; Roberto Hodara; Ross Fredenburg; Du-Chu Wu; Antonia Follenzi; William T Dauer; Serge Przedborski; Harry Ischiropoulos; Peter T Lansbury; David Sulzer; Ana Maria Cuervo
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.
The Journal of clinical investigation 2008;118(2):777-88.
2007: Ross A Fredenburg; Carla Rospigliosi; Robin K Meray; Jeffrey C Kessler; Hilal A Lashuel; David Eliezer; Peter T Lansbury
The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.
Biochemistry 2007;46(24):7107-18.
2007: Robin K Meray; Peter T Lansbury
Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1.
The Journal of biological chemistry 2007;282(14):10567-75.
2007: Michael J Volles; Peter T Lansbury
Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity.
Journal of molecular biology 2007;366(5):1510-22.
2007: Cristian Follmer; Luciana Romão; Carla M Einsiedler; Thaís C R Porto; Flávio Alves Lara; Marlos Moncores; Gilberto Weissmüller; Hilal A Lashuel; Peter T Lansbury; Vivaldo Moura Neto; Jerson L Silva; Débora Foguel
Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.
Biochemistry 2007;46(2):472-82.
2006: Sarah J Luchansky; Peter T Lansbury; Ross L Stein
Substrate recognition and catalysis by UCH-L1.
Biochemistry 2006;45(49):14717-25.
2006: Peter T Lansbury; Hilal A Lashuel
A century-old debate on protein aggregation and neurodegeneration enters the clinic.
Nature 2006;443(7113):774-9.
2006: Peter T Lansbury
Improving synaptic function in a mouse model of AD.
Cell 2006;126(4):655-7.
2006: Hilal A Lashuel; Peter T Lansbury
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
Quarterly reviews of biophysics 2006;39(2):167-201.
2006: Chittaranjan Das; Quyen Q Hoang; Cheryl A Kreinbring; Sarah J Luchansky; Robin K Meray; Soumya S Ray; Peter T Lansbury; Dagmar Ringe; Gregory A Petsko
Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4675-80.
2005: Soumya S Ray; Richard J Nowak; Robert H Brown; Peter T Lansbury
Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(10):3639-44.
2005: Peter T Lansbury; Tom Fagan
Your health in the 21st century. A fix for faulty proteins.
Newsweek 2005;145(26A):52.
2005: Michael J Volles; Peter T Lansbury
A computer program for the estimation of protein and nucleic acid sequence diversity in random point mutagenesis libraries.
Nucleic acids research 2005;33(11):3667-77.
2004: Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.
Science (New York, N.Y.) 2004;305(5688):1292-5.
2004: Peter T Lansbury
Back to the future: the 'old-fashioned' way to new medications for neurodegeneration.
Nature medicine 2004;10 Suppl():S51-7.
2004: Soumya S Ray; Richard J Nowak; Konstantin Strokovich; Robert H Brown; Thomas Walz; Peter T Lansbury
An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis.
Biochemistry 2004;43(17):4899-905.
2004: Soumya S Ray; Peter T Lansbury
A possible therapeutic target for Lou Gehrig's disease.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(16):5701-2.
2004: Jean-Christophe Rochet; Tiago Outeiro; Kelly A Conway; Tomas T Ding; Michael J Volles; Hilal A Lashuel; Robert M Bieganski; Susan L Lindquist; Peter T Lansbury
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Journal of molecular neuroscience : MN 2004;23(1-2):23-34.
2003: Indu Kheterpal; Hilal A Lashuel; Dean Hartley; Thomas Walz; Peter T Lansbury; Ronald B. Wetzel
Abeta protofibrils possess a stable core structure resistant to hydrogen exchange.
Biochemistry 2003;42(48):14092-8.
2003: Hilal A Lashuel; Dean Hartley; Benjamin M Petre; Joseph S Wall; Martha N Simon; Thomas Walz; Peter T Lansbury
Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores.
Journal of molecular biology 2003;332(4):795-808.
2003: Yichin Liu; Hilal A Lashuel; Sungwoon Choi; Xuechao Xing; April Case; Jake Ni; Li-An Yeh; Gregory D Cuny; Ross L Stein; Peter T Lansbury
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.
Chemistry & biology 2003;10(9):837-46.
2003: Débora Foguel; Marisa C Suarez; Astria Ferrão-Gonzales; Thais C R Porto; Leonardo Palmieri; Carla M Einsiedler; Leonardo R Andrade; Hilal A Lashuel; Peter T Lansbury; Jeffery W Kelly; Jerson L Silva
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(17):9831-6.
2003: Michael J Volles; Peter T Lansbury
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Biochemistry 2003;42(26):7871-8.
2003: June-Young Park; Peter T Lansbury
Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Biochemistry 2003;42(13):3696-700.
2003: Jeffrey C Kessler; Jean-Christophe Rochet; Peter T Lansbury
The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
Biochemistry 2003;42(3):672-8.
2003: Byron Caughey; Peter T Lansbury
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.
Annual review of neuroscience 2003;26():267-98.
2002: Yichin Liu; Lara Fallon; Hilal A Lashuel; Zhihua Liu; Peter T Lansbury
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.
Cell 2002;111(2):209-18.
2002: Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
Journal of molecular biology 2002;322(5):1089-102.
2002: Peter T Lansbury; Alexis Brice
Genetics of Parkinson's disease and biochemical studies of implicated gene products.
Current opinion in cell biology 2002;14(5):653-60.
2002: Magdalena Anguiano; Richard J Nowak; Peter T Lansbury
Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes.
Biochemistry 2002;41(38):11338-43.
2002: Tomas T Ding; Seung-Jae Lee; Jean-Christophe Rochet; Peter T Lansbury
Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
Biochemistry 2002;41(32):10209-17.
2002: Hilal A Lashuel; Dean Hartley; Benjamin M Petre; Thomas Walz; Peter T Lansbury
Neurodegenerative disease: amyloid pores from pathogenic mutations.
Nature 2002;418(6895):291.
2002: Peter T Lansbury; Alexis Brice
Genetics of Parkinson's disease and biochemical studies of implicated gene products.
Current opinion in genetics & development 2002;12(3):299-306.
2002: Michael J Volles; Peter T Lansbury
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
Biochemistry 2002;41(14):4595-602.
2002: Mark D Shtilerman; Tomas T Ding; Peter T Lansbury
Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
Biochemistry 2002;41(12):3855-60.
2001: Kelly A Conway; Jean-Christophe Rochet; R M Bieganski; Peter T Lansbury
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
Science (New York, N.Y.) 2001;294(5545):1346-9.
2001: Michael J Volles; Seung-Jae Lee; Jean-Christophe Rochet; M D Shtilerman; Tomas T Ding; Jeffrey C Kessler; Peter T Lansbury
Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Biochemistry 2001;40(26):7812-9.
2001: Peter T Lansbury
Following nature's anti-amyloid strategy.
Nature biotechnology 2001;19(2):112-3.
2000: Jean-Christophe Rochet; Kelly A Conway; Peter T Lansbury
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
Biochemistry 2000;39(35):10619-26.
2000: Youcef Fezoui; Dean Hartley; JD Harper; Bhavana Shivu; Dominic M Walsh; Margaret M Condron; Dennis J Selkoe; Peter T Lansbury; Anthony L Fink; David B Teplow
An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2000;7(3):166-78.
2000: M S Goldberg; Peter T Lansbury
Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
Nature cell biology 2000;2(7):E115-9.
2000: Kelly A Conway; JD Harper; Peter T Lansbury
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Biochemistry 2000;39(10):2552-63.
2000: Jean-Christophe Rochet; Peter T Lansbury
Amyloid fibrillogenesis: themes and variations.
Current opinion in structural biology 2000;10(1):60-8.
2000: Kelly A Conway; Seung-Jae Lee; Jean-Christophe Rochet; Tomas T Ding; Robin E Williamson; Peter T Lansbury
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(2):571-6.
2000: Kelly A Conway; Seung-Jae Lee; Jean-Christophe Rochet; Tomas T Ding; JD Harper; Robin E Williamson; Peter T Lansbury
Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants.
Annals of the New York Academy of Sciences 2000;920():42-5.
2000: Peter T Lansbury; Kenneth S Kosik
Neurodegeneration: new clues on inclusions.
Chemistry & biology 2000;7(1):R9-R12.
1999: Peter T Lansbury
Yeast prions: bungee cord domains' balancing act.
Current biology : CB 1999;9(22):R845-7.
1999: B Caughey; Gregory J Raymond; Suzette A Priola; David Kocisko; Richard E Race; RA Bessen; Peter T Lansbury; B Chesebro
Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update.
Molecular biotechnology 1999;13(1):45-55.
1999: Edward H Koo; Peter T Lansbury; J W Kelly
Amyloid diseases: abnormal protein aggregation in neurodegeneration.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(18):9989-90.
1999: W Zhen; H Han; M Anguiano; Cynthia A Lemere; C G Cho; Peter T Lansbury
Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain.
Journal of medicinal chemistry 1999;42(15):2805-15.
1999: JD Harper; S S Wong; C M Lieber; Peter T Lansbury
Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.
Biochemistry 1999;38(28):8972-80.
1999: Peter T Lansbury
Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(7):3342-4.
1998: Kelly A Conway; JD Harper; Peter T Lansbury
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Nature medicine 1998;4(11):1318-20.
1998: S J Lee; U Liyanage; P E Bickel; Weiming Xia; Peter T Lansbury; Kenneth S Kosik
A detergent-insoluble membrane compartment contains A beta in vivo.
Nature medicine 1998;4(6):730-4.
1997: JD Harper; C M Lieber; Peter T Lansbury
Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein.
Chemistry & biology 1997;4(12):951-9.
1997: Peter T Lansbury
Structural neurology: are seeds at the root of neuronal degeneration?
Neuron 1997;19(6):1151-4.
1997: Peter T Lansbury
Yeast prions: inheritance by seeded protein polymerization?
Current biology : CB 1997;7(10):R617-9.
1997: Peter T Lansbury
Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease.
Current opinion in chemical biology 1997;1(2):260-7.
1997: Gregory J Raymond; James Hope; David Kocisko; Suzette A Priola; Lynne D Raymond; Alex Bossers; James Ironside; Robert G Will; S G Chen; R B Petersen; Pierluigi Gambetti; Richard Rubenstein; Mari A Smits; Peter T Lansbury; Byron Caughey
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans.
Nature 1997;388(6639):285-8.
1997: Byron Caughey; Gregory J Raymond; David Kocisko; Peter T Lansbury
Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies.
Journal of virology 1997;71(5):4107-10.
1997: JD Harper; S S Wong; C M Lieber; Peter T Lansbury
Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.
Chemistry & biology 1997;4(2):119-25.
1997: JD Harper; Peter T Lansbury
Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.
Annual review of biochemistry 1997;66():385-407.
1996: P H Weinreb; W Zhen; A W Poon; K A Conway; Peter T Lansbury
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.
Biochemistry 1996;35(43):13709-15.
1996: David Kocisko; Peter T Lansbury; Byron Caughey
Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain.
Biochemistry 1996;35(41):13434-42.
1996: Peter T Lansbury; B Caughey
The double life of the prion protein.
Current biology : CB 1996;6(8):914-6.
1996: T T Ashburn; H Han; B F McGuinness; Peter T Lansbury
Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides.
Chemistry & biology 1996;3(5):351-8.
1995: Byron Caughey; David Kocisko; Gregory J Raymond; Peter T Lansbury
Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state.
Chemistry & biology 1995;2(12):807-17.
1995: Peter T Lansbury; P R Costa; J M Griffiths; E J Simon; M Auger; K J Halverson; David Kocisko; Zachary S Hendsch; T T Ashburn; RICHARD SPENCER
Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide.
Nature structural biology 1995;2(11):990-8.
1995: RA Bessen; David Kocisko; Gregory J Raymond; S Nandan; Peter T Lansbury; Byron Caughey
Non-genetic propagation of strain-specific properties of scrapie prion protein.
Nature 1995;375(6533):698-700.
1995: David Kocisko; Suzette A Priola; Gregory J Raymond; Bruce Chesebro; Peter T Lansbury; Byron Caughey
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(9):3923-7.
1995: H Han; P H Weinreb; Peter T Lansbury
The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?
Chemistry & biology 1995;2(3):163-9.
1995: Peter T Lansbury
Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies.
Arzneimittel-Forschung 1995;45(3A):432-4.
1995: K C Evans; E P Berger; C G Cho; Karl H Weisgraber; Peter T Lansbury
Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(3):763-7.
1995: Peter T Lansbury; Byron Caughey
The chemistry of scrapie infection: implications of the 'ice 9' metaphor.
Chemistry & biology 1995;2(1):1-5.
1994: Peter T Lansbury
Mechanism of scrapie replication.
Science (New York, N.Y.) 1994;265(5178):1510.
1994: David Kocisko; J H Come; Suzette A Priola; Bruce Chesebro; Gregory J Raymond; Peter T Lansbury; Byron Caughey
Cell-free formation of protease-resistant prion protein.
Nature 1994;370(6489):471-4.
1993: J T Jarrett; E P Berger; Peter T Lansbury
The C-terminus of the beta protein is critical in amyloidogenesis.
Annals of the New York Academy of Sciences 1993;695():144-8.
1993: J H Come; Paul E Fraser; Peter T Lansbury
A kinetic model for amyloid formation in the prion diseases: importance of seeding.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(13):5959-63.
1993: J T Jarrett; Peter T Lansbury
Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?
Cell 1993;73(6):1055-8.
1993: J T Jarrett; E P Berger; Peter T Lansbury
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease.
Biochemistry 1993;32(18):4693-7.
1992: J T Jarrett; Peter T Lansbury
Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB.
Biochemistry 1992;31(49):12345-52.
1992: Peter T Lansbury
In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information.
Biochemistry 1992;31(30):6865-70.
1992: A C Lellouch; Peter T Lansbury
A peptide model for the heparin binding site of antithrombin III.
Biochemistry 1992;31(8):2279-85.
1991: RICHARD SPENCER; K J Halverson; M Auger; A E McDermott; Robert G Griffin; Peter T Lansbury
An unusual peptide conformation may precipitate amyloid formation in Alzheimer's disease: application of solid-state NMR to the determination of protein secondary structure.
Biochemistry 1991;30(43):10382-7.
1990: K Halverson; Paul E Fraser; Daniel A Kirschner; Peter T Lansbury
Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments.
Biochemistry 1990;29(11):2639-44.